It is hard to believe how time flies, and that OncoOne already celebrated its 5th anniversary last month. Together with our team, we took this opportunity to commemorate this amazing accomplishment.

In just 5 years, we have raised €18M in funding from private investors and public grants in Austria, enabling us to rapidly develop our two optimized anti-oxMIF antibodies up to Phase 1 readiness and unveiled our innovative PreTarg-it® technology platform. From our humble beginnings to a motivated and diverse team of 14 talented scientists and administrative professionals, we are looking forward to what the future holds and remain committed to the mission of advancing novel and highly potent therapeutics to treat underserved patients.